FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christopher Cannon

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Dylan L Steen; Christopher P Cannon; Suhas S Lele; Banibrata Mukhopadhyay; Sabina A Murphy; Mohan M Rajapurkar; Benjamin M Scirica; David A Morrow
Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.
Payal Kohli; Gerald Maurer; Joao Morais; José C Nicolau; Ali Oto; Eric Reyes; Robert F Storey; Lars Wallentin; Dominick J Angiolillo; Diego Ardissino; Jay Horrow; Steen Husted; Stefan K James; Christopher P Cannon
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Michael Davidson; Antonio M Gotto; Elizabeth T Leary; Sherry Xueyu Liu; Yale B Mitchel; Sukrut Shah; Michael Stepanavage; Philip Barter; Eliot A Brinton; Christopher P Cannon; Hayes M Dansky
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christopher Cannon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Dylan L Steen; Christopher P Cannon; Suhas S Lele; Banibrata Mukhopadhyay; Sabina A Murphy; Mohan M Rajapurkar; Benjamin M Scirica; David A Morrow
Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.
Clinical cardiology 2013;36(3):139-45.
2013: Payal Kohli; Gerald Maurer; Joao Morais; José C Nicolau; Ali Oto; Eric Reyes; Robert F Storey; Lars Wallentin; Dominick J Angiolillo; Diego Ardissino; Jay Horrow; Steen Husted; Stefan K James; Christopher P Cannon
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Circulation 2013;127(6):673-80.
2013: Michael Davidson; Antonio M Gotto; Elizabeth T Leary; Sherry Xueyu Liu; Yale B Mitchel; Sukrut Shah; Michael Stepanavage; Philip Barter; Eliot A Brinton; Christopher P Cannon; Hayes M Dansky
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
Journal of lipid research 2013;54(2):467-72.
2012: Payal Kohli; Christopher P Cannon
The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data.
Clinical cardiology 2012;35(12):714-7.
2012: Owen Mogabgab; Satishkumar Mohanavelu; Marc S Sabatine; Stephen D Wiviott; Elliott M Antman; Christopher P Cannon; Robert P Giugliano; Eugene Braunwald
Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction.
Chronobiology international 2012;29(10):1390-6.
2012: Jonathan Grinstein; Christopher P Cannon
Aspirin resistance: current status and role of tailored therapy.
Clinical cardiology 2012;35(11):673-81.
2012: Hector M Medina; Eric D Peterson; lee schwamm; Deepak L Bhatt; Christopher P Cannon; Gregg C Fonarow; W Frank Peacock; Maria V Grau-Sepulveda; Adrian F Hernandez; Warren Laskey
Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease.
Clinical cardiology 2012;35(10):632-40.
2012: Keith A Somma; lee schwamm; Deepak L Bhatt; Christopher P Cannon; Margueritte Cox; Gregg C Fonarow; Adrian F Hernandez; Warren Laskey; W Frank Peacock; Eric D Peterson; Leslie A Saxon
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction.
Circulation. Cardiovascular quality and outcomes 2012;5(5):654-61.
2012: Samip Vasaiwala; Deepak L Bhatt; Christopher P Cannon; Gregg C Fonarow; Adrian F Hernandez; Warren Laskey; Li Liang; W Frank Peacock; Eric D Peterson; Sylvia E Rosas; Lee H Schwamm
Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program.
Clinical cardiology 2012;35(9):541-7.
2012: Christopher P Cannon; Payal Kohli
Danger ahead: watch out for indirect comparisons!
Journal of the American College of Cardiology 2012;60(8):747-8.
2012: An H Bui; Christopher P Cannon; Kausik K Ray; Nader Rifai; Marc S Sabatine; Marc P Bonaca; David A Morrow
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Journal of thrombosis and thrombolysis 2012;34(2):222-8.
2012: Michelle O'Donoghue; Rudolf Spacek; Eva Swahn; Ajay Vaidya; Fons Windhausen; Rizwan Afsal; Joakim Alfredsson; William E Boden; Eugene Braunwald; Christopher P Cannon; Tim C Clayton; Robbert J De Winter; Keith A A Fox; Bo Lagerqvist; Peter A McCullough; Sabina A Murphy; Marc S Sabatine
An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials.
Journal of the American College of Cardiology 2012;60(2):106-11.
2012: Christopher P Cannon; Paul J Cannon
Physiology. COX-2 inhibitors and cardiovascular risk.
Science (New York, N.Y.) 2012;336(6087):1386-7.
2012: Payal Kohli; Christopher P Cannon
A new approach to managing the 'statin-intolerant' patient?
European heart journal 2012;33(9):1040-3.
2012: Payal Kohli; Christopher P Cannon
Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding.
Nature reviews. Cardiology 2012;9(2):69-71.
2012: Dylan L Steen; Christopher P Cannon
Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins.
Reviews in cardiovascular medicine 2012;13(1):e48-51.
2012: Payal Kohli; Christopher P Cannon
Triglycerides: how much credit do they deserve?
The Medical clinics of North America 2012;96(1):39-55.
2011: Robert F Storey; Richard C Becker; Christopher P Cannon; Frank Cools; Hakan Emanuelsson; Robert A Harrington; Steen Husted; Stefan K James; Hugo A Katus; Nardev S Khurmi; Soo Teik Lim; Philippe Gabriel STEG; Lars Wallentin
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
The American journal of cardiology 2011;108(11):1542-6.
2011: Robert F Storey; Richard C Becker; Richard Cairns; Christopher P Cannon; Frank Cools; Anna Cooper; Håkan Emanuelsson; Robert A Harrington; Steen Husted; Stefan K James; Nardev S Khurmi; Philippe Gabriel STEG; Lars Wallentin
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
European heart journal 2011;32(23):2945-53.
2011: Apurva A Motivala; Eric D Peterson; Vankeepuram Srinivas; Adrian F Hernandez; Deepak L Bhatt; Christopher P Cannon; David Dai; Gregg C Fonarow
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care?
Journal of the American College of Cardiology 2011;58(17):1760-5.
2011: Michelle L O'Donoghue; Patrick Serruys; Ph Gabriel Steg; Elizabeth Tarka; Douglas Weaver; Harvey D White; Greg Cicconetti; Judith Hochman; Joel L Johnson; Mary Ann Lukas; Aldo P Maggioni; Christoph Bode; Eugene Braunwald; Christopher P Cannon
Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
American heart journal 2011;162(4):613-619.e1.
2011: Sean R Wilson; Marc S Sabatine; Stephen D Wiviott; Kausik K Ray; James A de Lemos; Shanggen Zhou; Nader Rifai; Christopher P Cannon; David A Morrow
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22).
American heart journal 2011;161(6):1147-55.e1.
2011: Babak Nazer; Kausik K Ray; Sarah Sloan; Benjamin M Scirica; David A Morrow; Christopher P Cannon; Eugene Braunwald
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
European heart journal 2011;32(11):1390-7.
2011: Farhad Abtahian; Benjamin Olenchock; Fang-Shu Ou; Michael C Kontos; Jorge F Saucedo; Benjamin M Scirica; Nihar Desai; Eric Peterson; Matthew Roe; Christopher P Cannon; Stephen D Wiviott
Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry).
The American journal of cardiology 2011;107(10):1441-6.
2011: Benjamin M Scirica; Christopher P Cannon; Håkan Emanuelsson; Eric L Michelson; Robert A Harrington; Steen Husted; Stefan James; Hugo Katus; Prem Pais; Dimitar Raev; Jindrich Spinar; Ph Gabriel Steg; Robert F Storey; Lars Wallentin
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.
Journal of the American College of Cardiology 2011;57(19):1908-16.
2011: Quynh A Truong; Annemarie Armani; Christopher P Cannon; Carolyn H McCabe; Sabina A Murphy
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Circulation. Cardiovascular quality and outcomes 2011;4(3):328-36.
2011: Christopher P Cannon
Clopidogrel: to test or not to test? That is the question--still.
Clinical chemistry 2011;57(5):659-61.
2011: Shaheeda Ahmed; C Michael Gibson; Christopher P Cannon; Sabina A Murphy; Marc S Sabatine
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.
Journal of thrombosis and thrombolysis 2011;31(4):493-500.
2011: Marc P Bonaca; David A Morrow; Eugene Braunwald; Christopher P Cannon; Songtao Jiang; Stephanie Breher; Marc S Sabatine; Tibor Kempf; Lars Wallentin; Kai C Wollert
Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22.
Arteriosclerosis, thrombosis, and vascular biology 2011;31(1):203-10.
2010: Christopher P Cannon; Sukrut Shah; Hayes M Dansky; Michael Davidson; Eliot A Brinton; Antonio M Gotto; Michael Stepanavage; Sherry Xueyu Liu; Patrice Gibbons; Tanya B Ashraf; Jennifer Zafarino; Yale Mitchel; Philip Barter
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
The New England journal of medicine 2010;363(25):2406-15.
2010: Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon
Clopidogrel with or without omeprazole in coronary artery disease.
The New England journal of medicine 2010;363(20):1909-17.
2010: Mitul B Kadakia; Nihar R Desai; Karen P Alexander; Anita Y Chen; JoAnne M Foody; Christopher P Cannon; Stephen D Wiviott; Benjamin M Scirica
Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines).
JACC. Cardiovascular interventions 2010;3(11):1166-77.
2010: Pradeep Natarajan; Christopher P Cannon
Could direct inhibition of inflammation be the "next big thing" in treating atherosclerosis?
Arteriosclerosis, thrombosis, and vascular biology 2010;30(11):2081-3.
2010: Loren Laine; Sean P Curtis; B Cryer; A Kaur; Christopher P Cannon
Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.
Alimentary pharmacology & therapeutics 2010;32(10):1240-8.
2010: Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul A Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
JAMA : the journal of the American Medical Association 2010;304(16):1821-30.
2010: Robert F Storey; Dominick J Angiolillo; Shankar B Patil; Bhaloo Desai; Rosemary Ecob; Steen Husted; Håkan Emanuelsson; Christopher P Cannon; Richard C Becker; Lars Wallentin
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Journal of the American College of Cardiology 2010;56(18):1456-62.
2010: Amit V Khera; Megan L Wolfe; Christopher P Cannon; Jie Qin; Daniel J Rader
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
The American journal of cardiology 2010;106(4):451-6.
2010: Benjamin M Scirica; David A Morrow; Christoph Bode; Witold Ruzyllo; Mikhail Ruda; Anthonius J M Oude Ophuis; Jose Lopez-Sendon; Karl Swedberg; Michal Ogorek; Nader Rifai; Valentina Lukashevich; Mojdeh Maboudian; Christopher P Cannon; Carolyn H McCabe; Eugene Braunwald
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
European heart journal 2010;31(16):1993-2005.
2010: Kausik K Ray; Babak Nazer; Richard Cairns; C Michael Gibson; Christopher P Cannon
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.
Journal of thrombosis and thrombolysis 2010;30(1):10-3.
2010: Alexander Thompson; Pei Gao; Lia Orfei; Sarah Watson; Emanuele Di Angelantonio; Stephen Kaptoge; Christie Ballantyne; Christopher P Cannon; Michael Criqui; Mary Cushman; Albert Hofman; Chris Packard; Simon G Thompson; Rory Collins; John Danesh
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
Lancet 2010;375(9725):1536-44.
2010: Robert M Califf; Yuliya Lokhnygina; Christopher P Cannon; Michael E Stepanavage; Carolyn H McCabe; Thomas A Musliner; Richard C Pasternak; Michael A Blazing; Robert P Giugliano; Robert A Harrington; Eugene Braunwald
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
American heart journal 2010;159(5):705-9.
2010: Christopher P Cannon
Balancing the benefits of statins versus a new risk-diabetes.
Lancet 2010;375(9716):700-1.
2010: Christopher P Cannon; Karen E Rhee; Robert M Califf; William E Boden; Alan T Hirsch; Mark J Alberts; Greg Cable; Mingyuan Shao; Erik Ohman; P Gabriel Steg; Kim A Eagle; Deepak L Bhatt
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
The American journal of cardiology 2010;105(4):445-52.
2010: Christopher P Cannon; Robert A Harrington; Stefan James; Diego Ardissino; Richard C Becker; Håkan Emanuelsson; Steen Husted; Hugo Katus; Matyas Keltai; Nardev S Khurmi; Frederic Kontny; Basil S. Lewis; Philippe Gabriel STEG; Robert F Storey; Daniel Wojdyla; Lars Wallentin
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Lancet 2010;375(9711):283-93.
2010: James R Harkness; Marc S Sabatine; Eugene Braunwald; David A Morrow; Sarah Sloan; Stephen D Wiviott; Robert P Giugliano; Elliott M Antman; Christopher P Cannon; Benjamin M Scirica
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction.
American heart journal 2010;159(1):55-62.
2009: Sabina A Murphy; Christopher P Cannon; Stephen D Wiviott; Carolyn H McCabe; Eugene Braunwald
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Journal of the American College of Cardiology 2009;54(25):2358-62.
2009: C Michael Gibson; Yuri B Pride; Claudia P Hochberg; Sarah Sloan; Marc S Sabatine; Christopher P Cannon
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Journal of the American College of Cardiology 2009;54(24):2290-5.
2009: Amit Kumar; Christopher P Cannon
Acute coronary syndromes: Diagnosis and management, part II.
Mayo Clinic proceedings. Mayo Clinic 2009;84(11):1021-36.
2009: Amit Kumar; Christopher P Cannon
Acute coronary syndromes: diagnosis and management, part I.
Mayo Clinic proceedings. Mayo Clinic 2009;84(10):917-38.
2009: Christopher P Cannon; Hayes M Dansky; Michael Davidson; Antonio M Gotto; Eliot A Brinton; A Lawrence Gould; Michael Stepanavage; Sherry Xueyu Liu; Sukrut Shah; Joseph Rubino; Patrice Gibbons; Anne Hermanowski-Vosatka; Bruce Binkowitz; Yale Mitchel; Philip Barter
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
American heart journal 2009;158(4):513-519.e3.
2009: Loren Laine; L Connors; M R Griffin; Sean P Curtis; A Kaur; Christopher P Cannon
Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines.
Alimentary pharmacology & therapeutics 2009;30(7):767-74.
2009: Amit Kumar; Gregg C Fonarow; Kim A Eagle; Alan T Hirsch; Robert M Califf; Mark J Alberts; William E Boden; P Gabriel Steg; Mingyuan Shao; Deepak L Bhatt; Christopher P Cannon
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
Critical pathways in cardiology 2009;8(3):104-11.
2009: Jessica L Mega; David A Morrow; Alison Brown; Christopher P Cannon; Marc S Sabatine
Identification of genetic variants associated with response to statin therapy.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(9):1310-5.
2009: Yuri B Pride; Evan Appelbaum; Erin E Lord; Sarah Sloan; Christopher P Cannon; Marc S Sabatine; C Michael Gibson
Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
The American journal of cardiology 2009;104(4):475-9.
2009: Robert F Storey; S Melissa Thornton; Rachael Lawrance; Steen Husted; Mark Wickens; Håkan Emanuelsson; Christopher P Cannon; Stan Heptinstall; Martin Armstrong
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Platelets 2009;20(5):341-8.
2009: Daniel E Forman; Christopher P Cannon; Adrian F Hernandez; Li Liang; Clyde W Yancy; Gregg C Fonarow
Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF).
American heart journal 2009;157(6):1010-7.
2009: David M Charytan; Lars Wallentin; Bo Lagerqvist; Rudolf Spacek; Robbert J De Winter; Noam M Stern; Eugene Braunwald; Christopher P Cannon; Niteesh K Choudhry
Early angiography in patients with chronic kidney disease: a collaborative systematic review.
Clinical journal of the American Society of Nephrology : CJASN 2009;4(6):1032-43.
2009: Deepak L Bhatt; eric peterson; Robert A Harrington; Fang-Shu Ou; Christopher P Cannon; C Michael Gibson; Neal S Kleiman; Ralph G Brindis; W Frank Peacock; Sorin J Brener; Venu Menon; Sidney C Smith; Charles V Pollack; W Brian Gibler; Erik Ohman; Matthew T Roe
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.
European heart journal 2009;30(10):1195-202.
2009: Christopher P Cannon
Can the polypill save the world from heart disease?
Lancet 2009;373(9672):1313-4.
2009: Patricia Tung; Stephen D Wiviott; Christopher P Cannon; Sabina A Murphy; Carolyn H McCabe; C Michael Gibson
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).
The American journal of cardiology 2009;103(8):1056-60.
2009: Nihar R Desai; Jessica L Mega; Songtao Jiang; Christopher P Cannon; Marc S Sabatine
Interaction between cigarette smoking and clinical benefit of clopidogrel.
Journal of the American College of Cardiology 2009;53(15):1273-8.
2009: Christopher P Cannon; James W Hoekstra; David M Larson; William A Mencia; Jeanne Cornish; Reshma D Carter; Carolyn A Berry; Rachel Bongiorno Karcher
Individual quality improvement in acute coronary syndromes: a performance improvement initiative.
Critical pathways in cardiology 2009;8(1):43-8.
2009: Charles V Pollack; Judd E Hollander; Anita Y Chen; eric peterson; Sripal Bangalore; Frank W Peacock; Christopher P Cannon; John G Canto; Brian W Gibler; Magnus E Ohman; Matthew T Roe
Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative.
Critical pathways in cardiology 2009;8(1):29-33.
2009: Kausik K Ray; Christopher P Cannon; Richard Cairns; David A Morrow; Paul M Ridker; Eugene Braunwald
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(3):424-30.
2009: Zeeshan Syed; Benjamin M Scirica; Satishkumar Mohanavelu; Phil Sung; Eric L Michelson; Christopher P Cannon; Peter H Stone; Collin M Stultz; John V Guttag
Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology.
The American journal of cardiology 2009;103(3):307-11.
2009: Benjamin A Olenchock; Gregg G Fonarow; Wenqin Pan; Adrian Hernandez; Christopher P Cannon
Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes.
The American journal of cardiology 2009;103(3):295-300.
2009: Benjamin M Scirica; Christopher P Cannon; Marc S Sabatine; Petr Jarolim; Sarah Sloane; Nader Rifai; Eugene Braunwald; David A Morrow
Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.
Clinical chemistry 2009;55(2):265-73.
2009: lee schwamm; Gregg C Fonarow; Mathew J Reeves; Wenqin Pan; Michael R Frankel; Eric E Smith; Gray Ellrodt; Christopher P Cannon; Li Liang; Eric Peterson; Kenneth LaBresh
Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack.
Circulation 2009;119(1):107-15.
2009: Quynh A Truong; Emily Siegel; Christopher P Cannon
Cardiac CT angiography--radiation dose-how effective are we in reducing radiation dose from cardiac CT angiography?
Reviews in cardiovascular medicine 2009;10(4):236-9.
2009: Quynh A Truong; David R Okada; Christopher P Cannon
Cardiac risk - coronary calcium scoring for all?
Reviews in cardiovascular medicine 2009;10(2):121-4.
2008: Christopher P Cannon
Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
The American journal of cardiology 2008;102(12A):5L-9L.
2008: Shaheeda Ahmed; Christopher P Cannon; Robert P Giugliano; Sabina A Murphy; David A Morrow; Elliott M Antman; Eugene Braunwald; C Michael Gibson
The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes.
International journal of cardiology 2008;131(1):105-12.
2008: Christopher P Cannon
Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit.
Critical pathways in cardiology 2008;7(4):223-31.
2008: Christopher P Cannon; Robert P Giugliano; Michael A Blazing; Robert A Harrington; John L Peterson; Christine McCrary Sisk; John Strony; Thomas A Musliner; Carolyn H McCabe; Enrico Veltri; Eugene Braunwald; Robert M Califf
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
American heart journal 2008;156(5):826-32.
2008: Loren Laine; Sean P Curtis; Michael Langman; Dennis M Jensen; Byron Cryer; Amarjot Kaur; Christopher P Cannon
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Gastroenterology 2008;135(5):1517-25.
2008: Benjamin A Olenchock; Stephen D Wiviott; Sabina A Murphy; Christopher P Cannon; Nader Rifai; Eugene Braunwald; David A Morrow
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16.
Journal of thrombosis and thrombolysis 2008;26(2):79-84.
2008: Roberto R Giraldez; Robert P Giugliano; Satishkumar Mohanavelu; Sabina A Murphy; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Journal of the American College of Cardiology 2008;52(11):914-20.
2008: Christopher P Cannon; Barry H Greenberg
Risk stratification and prognostic factors in the post-myocardial infarction patient.
The American journal of cardiology 2008;102(5A):13G-20G.
2008: Emmanouil Brilakis; James A de Lemos; Christopher P Cannon; Stephen D Wiviott; Sabina A Murphy; David A Morrow; Marc S Sabatine; Subhash Banerjee; Michael A Blazing; Robert M Califf; Eugene Braunwald
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
The American journal of cardiology 2008;102(5):552-8.
2008: Michelle O'Donoghue; William E Boden; Eugene Braunwald; Christopher P Cannon; Tim C Clayton; Robbert J De Winter; Keith A A Fox; Bo Lagerqvist; Peter A McCullough; Sabina A Murphy; Rudolf Spacek; Eva Swahn; Lars Wallentin; Fons Windhausen; Marc S Sabatine
Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis.
JAMA : the journal of the American Medical Association 2008;300(1):71-80.
2008: Jessica L Mega; David A Morrow; James A de Lemos; Satishkumar Mohanavelu; Christopher P Cannon; Marc S Sabatine
Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes.
Journal of the American College of Cardiology 2008;51(25):2422-9.
2008: Hani Jneid; Gregg C Fonarow; Christopher P Cannon; Igor F Palacios; Teoman Kilic; George V Moukarbel; Andrew O Maree; Kenneth LaBresh; Li Liang; L Kristin Newby; Gerald Fletcher; Laura Wexler; Eric Peterson
Impact of time of presentation on the care and outcomes of acute myocardial infarction.
Circulation 2008;117(19):2502-9.
2008: Marc S Sabatine; Hussam N Hamdalla; Shamir R Mehta; Keith A A Fox; Eric J Topol; Steven R Steinhubl; Christopher P Cannon
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
American heart journal 2008;155(5):910-7.
2008: C Michael Gibson; Yuri B Pride; Jacqueline Buros; Vijayalakshmi Kunadian; Matthew C Southard; Caitlin J Harrigan; Lauren N Ciaglo; Marc S Sabatine; Christopher P Cannon; Eugene Braunwald
Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy.
The American journal of cardiology 2008;101(9):1232-8.
2008: David A Morrow; Marc S Sabatine; Marie-Luise Brennan; James A de Lemos; Sabina A Murphy; Christian T Ruff; Nader Rifai; Christopher P Cannon; Stanley L Hazen
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.
European heart journal 2008;29(9):1096-102.
2008: Marc S Sabatine; David A Morrow; Luke J Higgins; Catherine MacGillivray; Wei Guo; Christophe Bode; Nader Rifai; Christopher P Cannon; Robert E Gerszten; Richard T Lee
Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.
Circulation 2008;117(15):1936-44.
2008: Amit Kumar; Christopher P Cannon
The role of statins in the prevention of heart failure after acute coronary syndrome.
Heart failure clinics 2008;4(2):129-39.
2008: Michelle O'Donoghue; David A Morrow; Christopher P Cannon; Wei Guo; Sabina A Murphy; C Michael Gibson; Marc S Sabatine
Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy.
European heart journal 2008;29(8):984-91.
2008: Christopher P Cannon
Combination therapy in the management of mixed dyslipidaemia.
Journal of internal medicine 2008;263(4):353-65.
2008: Eugene Braunwald; Dominick Angiolillo; Eric R Bates; Peter B Berger; Deepak Bhatt; Christopher P Cannon; Mark I Furman; Paul A Gurbel; Alan D Michelson; Eric Peterson; Stephen Wiviott
Antiplatelet therapy and platelet function testing.
Clinical cardiology 2008;31(3 Suppl 1):I36.
2008: Eugene Braunwald; Dominick Angiolillo; Eric R Bates; Peter B Berger; Deepak Bhatt; Christopher P Cannon; Mark I Furman; Paul A Gurbel; Alan D Michelson; Eric Peterson; Stephen Wiviott
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Clinical cardiology 2008;31(3 Suppl 1):I28-35.
2008: Eugene Braunwald; Dominick Angiolillo; Eric R Bates; Peter B Berger; Deepak Bhatt; Christopher P Cannon; Mark I Furman; Paul A Gurbel; Alan D Michelson; Eric Peterson; Stephen Wiviott
Investigating the mechanisms of hyporesponse to antiplatelet approaches.
Clinical cardiology 2008;31(3 Suppl 1):I21-7.
2008: Eugene Braunwald; Dominick Angiolillo; Eric R Bates; Peter B Berger; Deepak Bhatt; Christopher P Cannon; Mark I Furman; Paul A Gurbel; Alan D Michelson; Eric Peterson; Stephen Wiviott
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Clinical cardiology 2008;31(3 Suppl 1):I2-9.
2008: Eugene Braunwald; Dominick Angiolillo; Eric R Bates; Peter B Berger; Deepak Bhatt; Christopher P Cannon; Mark I Furman; Paul A Gurbel; Alan D Michelson; Eric Peterson; Stephen Wiviott
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.
Clinical cardiology 2008;31(3 Suppl 1):I17-20.
2008: Eugene Braunwald; Dominick Angiolillo; Eric R Bates; Peter B Berger; Deepak Bhatt; Christopher P Cannon; Mark I Furman; Paul A Gurbel; Alan D Michelson; Eric Peterson; Stephen Wiviott
Assessing the current role of platelet function testing.
Clinical cardiology 2008;31(3 Suppl 1):I10-6.
2008: Eugene Braunwald; Dominick Angiolillo; Eric R Bates; Peter B Berger; Deepak Bhatt; Christopher P Cannon; Mark I Furman; Paul A Gurbel; Alan D Michelson; Eric Peterson; Stephen Wiviott
Antiplatelet therapy and platelet function testing. Introduction.
Clinical cardiology 2008;31(3 Suppl 1):I1.
2008: Christopher P Cannon
Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit.
Critical pathways in cardiology 2008;7(1):43-81.
2008: C Michael Gibson; Yuri B Pride; Jacqueline Buros; Erin Lord; Amy Shui; Sabina A Murphy; Duane S Pinto; Peter Zimetbaum; Marc S Sabatine; Christopher P Cannon; Mark E Josephson
Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology 2008;51(5):546-51.
2008: Duane S Pinto; Ajay J Kirtane; Yuri B Pride; Sabina A Murphy; Marc S Sabatine; Christopher P Cannon; C Michael Gibson
Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study).
The American journal of cardiology 2008;101(3):303-7.
2008: Dalton S McLean; Shmuel Ravid; Michael A Blazing; Bernard Gersh; Amy Shui; Christopher P Cannon
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
American heart journal 2008;155(2):298-302.
2008: Christopher P Cannon; Subroto Acharjee
Percutaneous coronary intervention. Cardiovascular outcomes and long-term clopidogrel use after PCI in patients with diabetes.
Reviews in cardiovascular medicine 2008;9(4):280-2.
2008: Christopher P Cannon; Subroto Acharjee
Acute coronary syndrome. Cardiovascular events after clopidogrel discontinuation.
Reviews in cardiovascular medicine 2008;9(3):212-4.
2008: C Michael Gibson; Sabina A Murphy; Yuri B Pride; Ajay J Kirtane; Julian M Aroesty; Erica B Stein; Lauren N Ciaglo; Matthew C Southard; Marc S Sabatine; Christopher P Cannon; Eugene Braunwald
Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
American heart journal 2008;155(1):133-9.
2008: David A Morrow; Yunmei Wang; Kevin Croce; Masashi Sakuma; Marc S Sabatine; Huiyun Gao; Aruna D Pradhan; Aileen M Healy; Jacqueline Buros; Carolyn H McCabe; Peter Libby; Christopher P Cannon; Eugene Braunwald; Daniel I Simon
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial.
American heart journal 2008;155(1):49-55.
2007: Geoffrey C Schreiner; Loren Laine; Sabina A Murphy; Christopher P Cannon
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.
Critical pathways in cardiology 2007;6(4):169-72.
2007: Robert F Storey; Steen Husted; Robert A Harrington; Stan Heptinstall; Robert G Wilcox; Gary Peters; Mark Wickens; Håkan Emanuelsson; Paul A Gurbel; Peer Grande; Christopher P Cannon
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Journal of the American College of Cardiology 2007;50(19):1852-6.
2007: Christopher P Cannon; Steen Husted; Robert A Harrington; Benjamin M Scirica; Håkan Emanuelsson; Gary Peters; Robert F Storey
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
Journal of the American College of Cardiology 2007;50(19):1844-51.
2007: Christopher T Dibble; Eli V Gelfand; Christopher P Cannon
Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Current atherosclerosis reports 2007;9(5):359-66.
2007: Sabina A Murphy; Christopher P Cannon; Stephen D Wiviott; James A de Lemos; Michael A Blazing; Carolyn H McCabe; Robert M Califf; Eugene Braunwald
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
The American journal of cardiology 2007;100(7):1047-51.
2007: Benjamin M Scirica; David A Morrow; Christopher P Cannon; James A de Lemos; Sabina Murphy; Marc S Sabatine; Stephen D Wiviott; Nader Rifai; Carolyn H McCabe; Eugene Braunwald
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Clinical chemistry 2007;53(10):1800-7.
2007: Dalton S McLean; Marc S Sabatine; Wei Guo; Carolyn H McCabe; Christopher P Cannon
Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
Journal of thrombosis and thrombolysis 2007;24(2):85-91.
2007: E V Gelfand; Christopher P Cannon
Myocardial infarction: contemporary management strategies.
Journal of internal medicine 2007;262(1):59-77.
2007: Kausik K Ray; David A Morrow; Marc S Sabatine; Amy Shui; Nader Rifai; Christopher P Cannon; Eugene Braunwald
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Circulation 2007;115(24):3071-8.
2007: Kausik K Ray; Christopher P Cannon; David A Morrow; Ajay J Kirtane; Jacqueline Buros; Nader Rifai; Carolyn H McCabe; C Michael Gibson; Eugene Braunwald
Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18.
European heart journal 2007;28(7):806-13.
2007: Jonathan D Rich; John M Maraganore; Edward Young; Rosa-Maria Lidon; Burt Adelman; Paul Bourdon; Supoat Charenkavanich; Jack Hirsh; Pierre Theroux; Christopher P Cannon
Heparin resistance in acute coronary syndromes.
Journal of thrombosis and thrombolysis 2007;23(2):93-100.
2007: Scott D Lemme; Austin Kevin Raymond; Christopher P Cannon; Anne Normand; Kimberly C Smith; Dennis P M Hughes
Primary tuberculosis of bone mimicking a lytic bone tumor.
Journal of pediatric hematology/oncology 2007;29(3):198-202.
2007: Loren Laine; Sean P Curtis; Byron Cryer; Amarjot Kaur; Christopher P Cannon
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Lancet 2007;369(9560):465-73.
2007: Kausik K Ray; Christopher P Cannon
Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes.
Current treatment options in cardiovascular medicine 2007;9(1):46-51.
2007: Christopher P Cannon
Clopidogrel: who, when, and how?
Reviews in cardiovascular medicine 2007;8 Suppl 3():S27-34.
2007: Alexander Opotowsky; J Michael McWilliams; Christopher P Cannon
Gender differences in aspirin use among adults with coronary heart disease in the United States.
Journal of general internal medicine 2007;22(1):55-61.
2006: Christopher P Cannon; Deepak L Bhatt
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
The American journal of cardiology 2006;98(12A):36Q-41Q.
2006: Christopher P Cannon
Evolving management of ST-segment elevation myocardial infarction: update on recent data.
The American journal of cardiology 2006;98(12A):10Q-21Q.
2006: Kausik K Ray; Christopher P Cannon; Peter Ganz
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
The American journal of cardiology 2006;98(11A):18P-25P.
2006: Stephen D Wiviott; Christopher P Cannon
The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy.
Current opinion in lipidology 2006;17(6):626-30.
2006: Christopher P Cannon; Dalton S McLean
Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy.
The American journal of cardiology 2006;98(10A):33N-38N.
2006: Christopher P Cannon; Sean P Curtis; garret fitzgerald; Henry Krum; Amarjot Kaur; James A Bolognese; Alise S Reicin; Claire Bombardier; Michael E Weinblatt; Désirée van der Heijde; Erland Erdmann; Loren Laine
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Lancet 2006;368(9549):1771-81.
2006: Duane S Pinto; Ajay J Kirtane; Brahmajee K Nallamothu; Sabina A Murphy; David J Cohen; Roger J Laham; Donald E Cutlip; Eric R Bates; Paul D Frederick; Dave P Miller; Joseph P Carrozza; Elliott M Antman; Christopher P Cannon; C Michael Gibson
Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy.
Circulation 2006;114(19):2019-25.
2006: Benjamin M Scirica; Christopher P Cannon; Richard Cooper; Richard H Aster; Jacqueline Brassard; Carolyn H McCabe; Andrew Charlesworth; Allan M Skene; Eugene Braunwald
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Journal of thrombosis and thrombolysis 2006;22(2):95-102.
2006: Kausik K Ray; David A Morrow; Amy Shui; Nader Rifai; Christopher P Cannon
Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).
The American journal of cardiology 2006;98(7):861-5.
2006: Kausik K Ray; Christopher P Cannon
Intensive statin therapy for treating acute coronary syndromes.
Expert opinion on investigational drugs 2006;15(10):1151-9.
2006: Shaheeda Ahmed; Christopher P Cannon; Sabina A Murphy; Eugene Braunwald
Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial.
European heart journal 2006;27(19):2323-9.
2006: Kausik K Ray; Richard G Bach; Christopher P Cannon; Richard Cairns; Ajay J Kirtane; Stephen D Wiviott; Carolyn H McCabe; Eugene Braunwald; C Michael Gibson
Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS.
European heart journal 2006;27(19):2310-6.
2006: C Michael Gibson; Hung Q Ly; Sabina A Murphy; Lauren N Ciaglo; Matthew C Southard; Erica B Stein; Jacqueline Buros; Marc S Sabatine; Christopher P Cannon
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28).
The American journal of cardiology 2006;98(6):761-3.
2006: Ajay J Kirtane; Jonathan J Vafai; Sabina A Murphy; Julian M Aroesty; Marc S Sabatine; Christopher P Cannon; C Michael Gibson
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.
European heart journal 2006;27(17):2040-5.
2006: Michelle O'Donoghue; James A de Lemos; David A Morrow; Sabina A Murphy; Jacqueline Buros; Christopher P Cannon; Marc S Sabatine
Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
Circulation 2006;114(6):550-7.
2006: Christopher P Cannon; Sean P Curtis; James A Bolognese; Loren Laine
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
American heart journal 2006;152(2):237-45.
2006: Stephen D Wiviott; Christopher P Cannon
Update on lipid-lowering therapy and LDL-cholesterol targets.
Nature clinical practice. Cardiovascular medicine 2006;3(8):424-36.
2006: Benjamin M Scirica; Marc S Sabatine; David A Morrow; C Michael Gibson; Sabina A Murphy; Stephen D Wiviott; Robert P Giugliano; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.
Journal of the American College of Cardiology 2006;48(1):37-42.
2006: Hung Q Ly; Ajay J Kirtane; Sabina A Murphy; Jacqueline Buros; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials).
The American journal of cardiology 2006;98(1):1-5.
2006: Benjamin M Scirica; David A Morrow; Christopher P Cannon; Kausik K Ray; Marc S Sabatine; Petr Jarolim; Amy Shui; Carolyn H McCabe; Eugene Braunwald
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Journal of the American College of Cardiology 2006;47(11):2326-31.
2006: Eli V Gelfand; Christopher P Cannon
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
Journal of the American College of Cardiology 2006;47(10):1919-26.
2006: Raphaëlle Dumaine; C Michael Gibson; Sabina A Murphy; Matthew C Southard; Hung Q Ly; Carolyn H McCabe; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(5):315-22.
2006: Michelle O'Donoghue; David A Morrow; Marc S Sabatine; Sabina A Murphy; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
Circulation 2006;113(14):1745-52.
2006: Shaheeda Ahmed; Elliott M Antman; Sabina A Murphy; Robert P Giugliano; Christopher P Cannon; Harvey White; David A Morrow; Eugene Braunwald
Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials).
Journal of thrombosis and thrombolysis 2006;21(2):119-29.
2006: Stephen D Wiviott; James A de Lemos; Christopher P Cannon; Michael A Blazing; Sabina A Murphy; Carolyn H McCabe; Robert M Califf; Eugene Braunwald
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Circulation 2006;113(11):1406-14.
2006: Benjamin A Steinberg; William J French; Eric D Peterson; Paul D Frederick; Christopher P Cannon
Missed diagnosis of the diagnosis codes: comparison of International Classification of Diseases, 9th Revision coding and ST- versus non-ST-elevation myocardial infarction diagnosis in the National Registry of Myocardial Infarction.
Critical pathways in cardiology 2006;5(1):59-63.
2006: Eli V Gelfand; Christopher P Cannon
Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Expert opinion on investigational drugs 2006;15(3):307-15.
2006: James L Januzzi; L Kristin Newby; Sabina A Murphy; Karen Pieper; Elliott M Antman; David A Morrow; Marc S Sabatine; Erik Ohman; Christopher P Cannon; Eugene Braunwald
Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies.
American heart journal 2006;151(2):360-6.
2006: Marc S Sabatine; David A Morrow; Carolyn H McCabe; Elliott M Antman; C Michael Gibson; Christopher P Cannon
Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction.
American heart journal 2006;151(1):25-31.
2005: Marc S Sabatine; David A Morrow; Gilles Montalescot; Mikael Dellborg; Jose L Leiva-Pons; Mátyás Keltai; Sabina A Murphy; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Circulation 2005;112(25):3846-54.
2005: Christopher P Cannon
Update to International Classification of Diseases, 9th Revision codes: distinguishes STEMI from NSTEMI.
Critical pathways in cardiology 2005;4(4):185-6.
2005: Jason W Ryan; Eric D Peterson; Anita Y Chen; Matthew T Roe; Erik Ohman; Christopher P Cannon; Peter B Berger; Jorge F Saucedo; Elizabeth R DeLong; Sharon-Lise T Normand; Charles V Pollack; David J Cohen
Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry.
Circulation 2005;112(20):3049-57.
2005: Christopher P Cannon
Acute coronary syndromes: risk stratification and initial management.
Cardiology clinics 2005;23(4):401-9, v.
2005: Kausik K Ray; Christopher P Cannon
Optimal goals for statin use in patients with coronary artery disease.
Current opinion in cardiology 2005;20(6):525-9.
2005: Kausik K Ray; Christopher P Cannon
The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.
Journal of the American College of Cardiology 2005;46(8):1425-33.
2005: Kausik K Ray; Christopher P Cannon; Richard Cairns; David A Morrow; Nader Rifai; Ajay J Kirtane; Carolyn H McCabe; Allan M Skene; C Michael Gibson; Paul M Ridker; Eugene Braunwald
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Journal of the American College of Cardiology 2005;46(8):1417-24.
2005: Stephen D Wiviott; Christopher P Cannon; David A Morrow; Kausik K Ray; Marc A Pfeffer; Eugene Braunwald
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Journal of the American College of Cardiology 2005;46(8):1411-6.
2005: Kausik K Ray; Christopher P Cannon; Carolyn H McCabe; Richard Cairns; Andrew M Tonkin; Frank M Sacks; Graham Jackson; Eugene Braunwald
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Journal of the American College of Cardiology 2005;46(8):1405-10.
2005: Kausik K Ray; Christopher P Cannon
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
The American journal of cardiology 2005;96(5A):54F-60F.
2005: Nazanin Moghbeli; Ajay J Kirtane; Kausik K Ray; Sabina A Murphy; C Michael Gibson; Eugene Braunwald; Christopher P Cannon
C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial).
The American journal of cardiology 2005;96(5):635-8.
2005: Christopher P Cannon; Shamir R Mehta; Sary F Aranki
Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.
The Annals of thoracic surgery 2005;80(2):768-79.
2005: Ajay J Kirtane; David M Leder; Sushrut S Waikar; Glenn M Chertow; Kausik K Ray; Duane S Pinto; Dimitrios Karmpaliotis; Andrew J Burger; Sabina A Murphy; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates.
Journal of the American College of Cardiology 2005;45(11):1781-6.
2005: Christopher P Cannon
Implementation of critical pathways in the "real world".
Critical pathways in cardiology 2005;4(2):110-4.
2005: Kausik K Ray; Christopher P Cannon
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.
Expert opinion on pharmacotherapy 2005;6(6):915-27.
2005: Benjamin M Scirica; Christopher P Cannon
Treatment of elevated cholesterol.
Circulation 2005;111(21):e360-3.
2005: Paul M Ridker; David A Morrow; Lynda M Rose; Nader Rifai; Christopher P Cannon; Eugene Braunwald
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Journal of the American College of Cardiology 2005;45(10):1644-8.
2005: James L Januzzi; Jacqueline Buros; Christopher P Cannon
Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial.
Clinical cardiology 2005;28(5):238-42.
2005: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; J Thomas Grayston; Brent Muhlestein; Robert P Giugliano; Richard Cairns; Allan M Skene
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.
The New England journal of medicine 2005;352(16):1646-54.
2005: Marc S Sabatine; Christopher P Cannon; C Michael Gibson; Jose L López-Sendón; Gilles Montalescot; Pierre Theroux; Marc J Claeys; Frank Cools; Karen A Hill; Allan M Skene; Carolyn H McCabe; Eugene Braunwald
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
The New England journal of medicine 2005;352(12):1179-89.
2005: Marc S Sabatine; Gavin J Blake; Mark H Drazner; David A Morrow; Benjamin M Scirica; Sabina A Murphy; Carolyn H McCabe; William S Weintraub; C Michael Gibson; Christopher P Cannon
Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment.
Circulation 2005;111(10):1217-24.
2005: Christopher P Cannon
What is the optimal timing of clopidogrel in acute coronary syndromes?
Critical pathways in cardiology 2005;4(1):46-50.
2005: Kausik K Ray; Christopher P Cannon
Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease.
Critical pathways in cardiology 2005;4(1):43-5.
2005: Charles S Smith; Christopher P Cannon; Carolyn H McCabe; Sabina A Murphy; Jane Bentley; Eugene Braunwald
Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial.
American heart journal 2005;149(3):444-50.
2005: Marc S Sabatine; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon
Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial.
American heart journal 2005;149(2):227-33.
2005: C Michael Gibson; Ajay J Kirtane; Keith Boundy; Hung Ly; Dimitrios Karmpaliotis; Sabina A Murphy; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients.
Journal of the American College of Cardiology 2005;45(3):357-62.
2005: Ajay J Kirtane; Ioanna Kosmidou; Dimitrios Karmpaliotis; Sabina A Murphy; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald; C Michael Gibson
Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy.
The American journal of cardiology 2005;95(3):337-42.
2005: Ajay J Kirtane; Pedro Martinezclark; Aref M Rahman; Kausik K Ray; Dimitrios Karmpaliotis; Sabina A Murphy; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Matthew T Roe; Robert A Harrington; Erik Ohman; Eugene Braunwald; C Michael Gibson
Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology 2005;45(2):321-3.
2005: Ajay J Kirtane; Aaron Weisbord; Dimitrios Karmpaliotis; Sabina A Murphy; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Erik Ohman; Matthew T Roe; Eugene Braunwald; C Michael Gibson
Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction.
The American journal of cardiology 2005;95(2):224-7.
2005: Paul M Ridker; Christopher P Cannon; David Morrow; Nader Rifai; Lynda M Rose; Carolyn H McCabe; Marc A Pfeffer; Eugene Braunwald
C-reactive protein levels and outcomes after statin therapy.
The New England journal of medicine 2005;352(1):20-8.
2004: Minang P Turakhia; Sabina A Murphy; Tina L Pinto; Elliott M Antman; Robert P Giugliano; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction.
The American journal of cardiology 2004;94(11):1406-10.
2004: Kausik K Ray; Christopher P Cannon
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Current opinion in lipidology 2004;15(6):637-43.
2004: C Michael Gibson; Raphaelle L Dumaine; Eli V Gelfand; Sabina A Murphy; David A Morrow; Stephen D Wiviott; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials.
European heart journal 2004;25(22):1998-2005.
2004: Dimitrios Karmpaliotis; Minang P Turakhia; Ajay J Kirtane; Sabina A Murphy; Ioanna Kosmidou; David A Morrow; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald; C Michael Gibson
Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction.
The American journal of cardiology 2004;94(9):1113-7.
2004: Kausik K Ray; Christopher P Cannon
Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation.
Journal of thrombosis and thrombolysis 2004;18(2):89-101.
2004: David A Morrow; Marc S Sabatine; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; Pierre Theroux
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
The American journal of cardiology 2004;94(6):774-6.
2004: C Michael Gibson; Sabina A Murphy; Ajay J Kirtane; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology 2004;44(5):980-7.
2004: Stephen D Wiviott; David A Morrow; Paul D Frederick; Robert P Giugliano; C Michael Gibson; Carolyn H McCabe; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology 2004;44(4):783-9.
2004: Richard G Bach; Christopher P Cannon; William S Weintraub; Peter M DiBattiste; Laura A Demopoulos; H Vernon Anderson; Paul T DeLucca; Elizabeth M Mahoney; Sabina A Murphy; Eugene Braunwald
The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes.
Annals of internal medicine 2004;141(3):186-95.
2004: David A Morrow; Elliott M Antman; Sabina A Murphy; Susan F Assmann; Robert P Giugliano; Christopher P Cannon; C Michael Gibson; Carolyn H McCabe; Hal V Barron; Frans Van de Werf; Eugene Braunwald
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies.
European heart journal 2004;25(13):1139-45.
2004: Howard C Herrmann; Sabina A Murphy; Peter M DiBattiste; Paul T Delucca; Laura A Demopoulos; C Michael Gibson; Christopher P Cannon
Greater benefit of early invasive strategy for unstable angina and non-ST elevation myocardial infarction in United States compared with non-United States patients: a TACTICS-TIMI 18 substudy.
Critical pathways in cardiology 2004;3(2):95-100.
2004: Christopher P Cannon
Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapy.
Critical pathways in cardiology 2004;3(2):83-6.
2004: Ajay J Kirtane; Anh Bui; Sabina A Murphy; Dimitrios Karmpaliotis; Ioanna Kosmidou; Keith Boundy; Aref Rahman; Duane S Pinto; Julian M Aroesty; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; C Michael Gibson
Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction.
Journal of thrombosis and thrombolysis 2004;17(3):177-84.
2004: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
The New England journal of medicine 2004;350(15):1495-504.
2004: C Michael Gibson; Juhana Karha; Sabina A Murphy; James A de Lemos; David A Morrow; Robert P Giugliano; Matthew T Roe; Robert A Harrington; Christopher P Cannon; Elliott M Antman; Robert M Califf; Eugene Braunwald
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.
Journal of the American College of Cardiology 2004;43(7):1170-6.
2004: Marc S Sabatine; David A Morrow; Robert P Giugliano; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; William S Weintraub; Carolyn H McCabe; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Circulation 2004;109(7):874-80.
2004: Stephen D Wiviott; Christopher P Cannon; David A Morrow; Sabina A Murphy; C Michael Gibson; Carolyn H McCabe; Marc S Sabatine; Nader Rifai; Robert P Giugliano; Peter M DiBattiste; Laura A Demopoulos; Elliott M Antman; Eugene Braunwald
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.
Circulation 2004;109(5):580-6.
2004: Christopher P Cannon
Utilization of guidelines and computer-based technology to achieve optimal care in atherothrombotic vascular disease.
Journal of thrombosis and thrombolysis 2004;17(1):45-9.
2004: Eli V Gelfand; Christopher P Cannon
Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT.
American heart journal 2004;147(2):202-9.
2003: Christopher P Cannon
The next step in cardiovascular protection.
Atherosclerosis. Supplements 2003;4(5):3-9.
2003: C Michael Gibson; Duane S Pinto; Sabina A Murphy; David A Morrow; Hans-Peter Hobbach; Stephen D Wiviott; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality.
Journal of the American College of Cardiology 2003;42(9):1535-43.
2003: Christopher P Cannon
Treatment algorithms and critical pathways for acute coronary syndromes.
Seminars in vascular medicine 2003;3(4):425-32.
2003: James L Januzzi; Christopher P Cannon; Pierre Theroux; William E Boden
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
American heart journal 2003;146(5):764-74.
2003: Juhana Karha; Sabina A Murphy; Ajay J Kirtane; James A de Lemos; Julian M Aroesty; Christopher P Cannon; Elliott M Antman; Eugene Braunwald; C Michael Gibson
Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction.
The American journal of cardiology 2003;92(8):913-8.
2003: Christopher P Cannon
PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome.
Critical pathways in cardiology 2003;2(3):188-96.
2003: Christopher P Cannon; Eugene Braunwald
Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) acute coronary syndromes Critical Pathway Toolkit.
Critical pathways in cardiology 2003;2(3):153-77.
2003: Christopher P Cannon
Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II.
Clinical cardiology 2003;26(9):401-6.
2003: Christopher P Cannon
Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I.
Clinical cardiology 2003;26(8):358-64.
2003: C Michael Gibson; Juhana Karha; Sabina A Murphy; David James; David A Morrow; Christopher P Cannon; Robert P Giugliano; Elliott M Antman; Eugene Braunwald
Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials.
Journal of the American College of Cardiology 2003;42(1):7-16.
2003: Christopher P Cannon
Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies.
The American journal of geriatric cardiology 2003;12(4):259-62.
2003: Christopher P Cannon; Alexander G G Turpie
Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy.
Circulation 2003;107(21):2640-5.
2003: C Michael Gibson; Ajay J Kirtane; Sabina A Murphy; Juhana Karha; Christopher P Cannon; Robert P Giugliano; Matthew T Roe; Robert A Harrington; Erik Ohman; Elliott M Antman
Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture.
Journal of thrombosis and thrombolysis 2003;15(3):189-96.
2003: Graham C Wong; Daniel Frisch; Sabina A Murphy; Marc S Sabatine; Rupal Pai; David James; Nicole Kraimer; Peter T Katsiyiannis; Susan J Marble; Peter M DiBattiste; Laura A Demopoulos; Steven G Gourlay; Hal V Barron; Christopher P Cannon; C Michael Gibson
Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction.
The American journal of cardiology 2003;91(10):1163-7.
2003: David A Morrow; James A de Lemos; Marc S Sabatine; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Eugene Braunwald
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.
Journal of the American College of Cardiology 2003;41(8):1264-72.
2003: Christopher P Cannon
Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial.
Journal of the American College of Cardiology 2003;41(4 Suppl S):43S-48S.
2003: Christopher P Cannon
Critical pathways for acute myocardial infarction.
Reviews in cardiovascular medicine 2003;4 Suppl 3():S47-53.
2003: Maria Cecilia Bahit; Christopher P Cannon; Elliott M Antman; Sabina A Murphy; C Michael Gibson; Carolyn H McCabe; Eugene Braunwald
Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry.
American heart journal 2003;145(1):109-17.
2002: Ruchira Glaser; Howard C Herrmann; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Christopher P Cannon; Eugene Braunwald
Benefit of an early invasive management strategy in women with acute coronary syndromes.
JAMA : the journal of the American Medical Association 2002;288(24):3124-9.
2002: James L Januzzi; Christopher P Cannon; Peter M DiBattiste; Sabina Murphy; William Weintraub; Eugene Braunwald
Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).
The American journal of cardiology 2002;90(11):1246-9.
2002: Marc S Sabatine; David A Morrow; Christopher P Cannon; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; Eugene Braunwald; C Michael Gibson
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy.
Journal of the American College of Cardiology 2002;40(10):1761-8.
2002: Elizabeth M Mahoney; Claudine Jurkovitz; Haitao Chu; Edmund R Becker; Steven D Culler; Andrzej S Kosinski; Debbie H Robertson; Charles Alexander; Soma Nag; John R Cook; Laura A Demopoulos; Peter M DiBattiste; Christopher P Cannon; William S Weintraub
Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.
JAMA : the journal of the American Medical Association 2002;288(15):1851-8.
2002: Benjamin M Scirica; Christopher P Cannon; Carolyn H McCabe; Sabina A Murphy; H Vernon Anderson; William J Rogers; Peter H Stone; Eugene Braunwald
Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification.
The American journal of cardiology 2002;90(8):821-6.
2002: Brad G Angeja; James de Lemos; Sabina A Murphy; Susan J Marble; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy.
American heart journal 2002;144(4):649-56.
2002: Sabina A Murphy; Christopher Chen; Christopher P Cannon; Elliott M Antman; C Michael Gibson
Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction.
The American journal of cardiology 2002;90(7):766-70.
2002: Christopher P Cannon
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
The American journal of cardiology 2002;90(7):760-2.
2002: Benjamin M Scirica; Christopher P Cannon; C Michael Gibson; Sabina A Murphy; David J Moliterno; H Vernon Anderson; FV Aguirre; Christopher B Granger; Costas T Lambrew; LeRoy E Rabbani; Shelly K Sapp; Joan E Booth; James J Ferguson; Eugene Braunwald
Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries.
Critical pathways in cardiology 2002;1(3):150-8.
2002: Benjamin M Scirica; Christopher P Cannon; Elliott M Antman; Sabina A Murphy; David A Morrow; Marc S Sabatine; Carolyn H McCabe; C Michael Gibson; Eugene Braunwald
Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry.
The American journal of cardiology 2002;90(3):303-5.
2002: Graham C Wong; David A Morrow; Sabina Murphy; Nicole Kraimer; Rupal Pai; David James; Debbie H Robertson; Laura A Demopoulos; Peter M DiBattiste; Christopher P Cannon; C Michael Gibson
Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction.
Circulation 2002;106(2):202-7.
2002: Christopher P Cannon
Palm Pilot programs to improve quality of care in acute coronary syndromes.
Critical pathways in cardiology 2002;1(2):113-5.
2002: Maria Cecilia Bahit; Sabina A Murphy; C Michael Gibson; Christopher P Cannon
Critical pathway for acute ST-segment elevation myocardial infarction: estimating its potential impact in the TIMI 9 Registry.
Critical pathways in cardiology 2002;1(2):107-12.
2002: Brad G Angeja; Sarah Kermgard; Michael S Chen; Matthew McKay; Sabina A Murphy; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
The smoker's paradox: insights from the angiographic substudies of the TIMI trials.
Journal of thrombosis and thrombolysis 2002;13(3):133-9.
2002: Robert A Kloner; Ken Poole; Thomas Shook; Karin Przyklenk; Kitty Perritt; Christopher P Cannon
Comparison of acute myocardial infarct size in patients > or =65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period.
The American journal of cardiology 2002;89(11):1291-3.
2002: Christopher P Cannon; Mary H Hand; Raymond Bahr; William E Boden; Robert H Christenson; W Brian Gibler; Kim A Eagle; Costas T Lambrew; Thomas H Lee; Bruce MacLeod; Joseph P Ornato; Harry P Selker; Pamela Steele; Robert J Zalenski
Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program.
American heart journal 2002;143(5):777-89.
2002: C Michael Gibson; Christopher P Cannon; Sabina A Murphy; Susan J Marble; Hal V Barron; Eugene Braunwald
Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction.
Circulation 2002;105(16):1909-13.
2002: Marc S Sabatine; David A Morrow; James A de Lemos; C Michael Gibson; Sabina A Murphy; Nader Rifai; Carolyn McCabe; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.
Circulation 2002;105(15):1760-3.
2002: Christopher P Cannon; Carolyn H McCabe; Rene Belder; Jeanne Breen; Eugene Braunwald
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
The American journal of cardiology 2002;89(7):860-1.
2002: Christopher P Cannon; Joseph P Ornato
How to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) Program.
Critical pathways in cardiology 2002;1(1):53-60.
2002: Christopher P Cannon; Maria Cecilia Bahit; J Mark Haugland; Timothy D Henry; Marc J Schweiger; George R McKendall; Prediman K Shah; Sabina Murphy; C Michael Gibson; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry.
Critical pathways in cardiology 2002;1(1):44-52.
2002: Christopher P Cannon
Critical pathway for unstable angina and non-ST elevation myocardial infarction: February 2002.
Critical pathways in cardiology 2002;1(1):12-21.
2002: C Michael Gibson; Michael Chen; Brad G Angeja; Sabina A Murphy; Susan J Marble; Hal V Barron; Christopher P Cannon
Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery.
Journal of thrombosis and thrombolysis 2002;13(1):9-12.
2001: N K Sekaran; David J Moliterno; J J Ferguson; Nathan R Every; H V Anderson; FV Aguirre; William J French; Shelly K Sapp; Joan E Booth; Christopher B Granger; Christopher P Cannon
"Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry.
Journal of thrombosis and thrombolysis 2001;12(3):207-16.
2001: David A Morrow; Christopher P Cannon; Nader Rifai; MJ Frey; R Vicari; Nasser Lakkis; Debbie H Robertson; D A Hille; Paul T DeLucca; Peter M DiBattiste; Laura A Demopoulos; William S Weintraub; Eugene Braunwald
Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.
JAMA : the journal of the American Medical Association 2001;286(19):2405-12.
2001: J A de Lemos; David A Morrow; J H Bentley; T Omland; Marc S Sabatine; Carolyn H McCabe; C Hall; Christopher P Cannon; Eugene Braunwald
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
The New England journal of medicine 2001;345(14):1014-21.
2001: David A Morrow; Elliott M Antman; L Parsons; James A de Lemos; Christopher P Cannon; Robert P Giugliano; Carolyn H McCabe; H V Barron; Eugene Braunwald
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3.
JAMA : the journal of the American Medical Association 2001;286(11):1356-9.
2001: Christopher P Cannon; William S Weintraub; Laura A Demopoulos; R Vicari; MJ Frey; Nasser Lakkis; Franz-Josef Neumann; Debbie H Robertson; Paul T DeLucca; Peter M DiBattiste; C Michael Gibson; Eugene Braunwald
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
The New England journal of medicine 2001;344(25):1879-87.
2001: Robert A Kloner; Thomas Shook; Christopher P Cannon; Karin Przyklenk
Ischemic preconditioning: implications for the geriatric heart.
The American journal of geriatric cardiology 2001;10(3):145-8; quiz 149-51.
2001: Robert P Giugliano; Carolyn H McCabe; Elliott M Antman; Christopher P Cannon; Frans Van de Werf; R G Wilcox; Eugene Braunwald
Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
American heart journal 2001;141(5):742-50.
2001: Christopher P Cannon; Carolyn H McCabe; Robert G Wilcox; J H Bentley; Eugene Braunwald
Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.
The American journal of cardiology 2001;87(5):636-9, A10.
2001: F Wang-Clow; NL Fox; Christopher P Cannon; C Michael Gibson; S Berioli; Erich Bluhmki; Thierry Danays; Eugene Braunwald; Frans Van de Werf; D C Stump
Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.
American heart journal 2001;141(1):33-40.
2000: C Michael Gibson; M Anshelevich; S Murphy; L Luu; C Hynes; J Kliris; S Kermgard; M H Otten; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction.
The American journal of cardiology 2000;86(12):1378-9, A5.
2000: Christopher P Cannon
Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents.
American heart journal 2000;140(6 Suppl):S154-60.
2000: David A Morrow; Elliott M Antman; Milenko J Tanasijevic; Nader Rifai; James A de Lemos; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy.
Journal of the American College of Cardiology 2000;36(6):1812-7.
2000: Hal V Barron; Christopher P Cannon; Sabina A Murphy; Eugene Braunwald; C Michael Gibson
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy.
Circulation 2000;102(19):2329-34.
2000: Christopher P Cannon
Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Clinical cardiology 2000;23 Suppl 6():VI-14-7.
2000: Christopher P Cannon
Multimodality reperfusion therapy for acute myocardial infarction.
American heart journal 2000;140(5):707-16.
2000: Christopher P Cannon; Assaad Sayah; Ron M Walls
ER TIMI-19: testing the reality of prehospital thrombolysis.
The Journal of emergency medicine 2000;19(3 Suppl):21S-25S.
2000: Christopher P Cannon; Carolyn H McCabe; Robert G Wilcox; A Langer; A Caspi; P Berink; J Lopez-Sendon; J Toman; A Charlesworth; R J Anders; J C Alexander; Allan M Skene; Eugene Braunwald
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Circulation 2000;102(2):149-56.
2000: J Llevadot; Robert P Giugliano; Carolyn H McCabe; Christopher P Cannon; Elliott M Antman; S Murphy; C Michael Gibson
Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials).
The American journal of cardiology 2000;85(12):1409-13.
2000: Christopher P Cannon; C Michael Gibson; Costas T Lambrew; DA Shoultz; D Levy; William J French; Joel M Gore; W D Weaver; W J Rogers; Alan J Tiefenbrunn
Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction.
JAMA : the journal of the American Medical Association 2000;283(22):2941-7.
2000: SA Coulter; Christopher P Cannon; K A Ault; Elliott M Antman; Frans Van de Werf; A A Jennifer Adgey; C Michael Gibson; Robert P Giugliano; Mary Ann Mascelli; J Scherer; Elliot S Barnathan; Eugene Braunwald; N S Kleiman
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
Circulation 2000;101(23):2690-5.
2000: N B Modi; NL Fox; F W Clow; P Tanswell; Christopher P Cannon; F Van de Werf; Eugene Braunwald
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
Journal of clinical pharmacology 2000;40(5):508-15.
2000: Christopher P Cannon
Thrombolysis medication errors: benefits of bolus thrombolytic agents.
The American journal of cardiology 2000;85(8A):17C-22C.
2000: David A Morrow; Nader Rifai; Elliott M Antman; D L Weiner; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy.
Journal of the American College of Cardiology 2000;35(2):358-62.
2000: C Michael Gibson; Christopher P Cannon; Sabina A Murphy; KA Ryan; R Mesley; Susan J Marble; Carolyn H McCabe; Frans Van de Werf; Eugene Braunwald
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.
Circulation 2000;101(2):125-30.
1999: Benjamin M Scirica; David J Moliterno; Nathan R Every; H V Anderson; FV Aguirre; Christopher B Granger; Costas T Lambrew; L E Rabbani; Shelly K Sapp; Joan E Booth; James J Ferguson; Christopher P Cannon
Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry.
American heart journal 1999;138(6 Pt 1):1065-72.
1999: Benjamin M Scirica; David J Moliterno; Nathan R Every; H Vernon Anderson; FV Aguirre; Christopher B Granger; Costas T Lambrew; L E Rabbani; A Arnold; Shelly K Sapp; Joan E Booth; James J Ferguson; Christopher P Cannon
Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators.
The American journal of cardiology 1999;84(10):1145-50.
1999: Christopher P Cannon
Diagnosis and management of patients with unstable angina.
Current problems in cardiology 1999;24(11):681-744.
1999: C Michael Gibson; Christopher P Cannon; Sabina A Murphy; A A Adgey; MJ Schweiger; Rafael Sequeira; G Grollier; NL Fox; S Berioli; W D Weaver; Frans Van de Werf; Eugene Braunwald
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.
The American journal of cardiology 1999;84(9):976-80.
1999: C Michael Gibson; S Murphy; Ian B A Menown; Rafael Sequeira; R Greene; Frans Van de Werf; M J Schweiger; M Ghali; MJ Frey; KA Ryan; Susan J Marble; Robert P Giugliano; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction.
Journal of the American College of Cardiology 1999;34(5):1403-12.
1999: Christopher P Cannon
Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction.
Journal of the American College of Cardiology 1999;34(5):1395-402.
1999: C Michael Gibson; KA Ryan; Sabina A Murphy; R Mesley; Susan J Marble; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction.
Journal of the American College of Cardiology 1999;34(4):974-82.
1999: Milenko J Tanasijevic; Christopher P Cannon; Elliott M Antman; DR Wybenga; George A Fischer; C Grudzien; C Michael Gibson; James W Winkelman; Eugene Braunwald
Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B.
Journal of the American College of Cardiology 1999;34(3):739-47.
1999: Christopher P Cannon
Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.
Clinical cardiology 1999;22(8 Suppl):IV37-43.
1999: Christopher P Cannon
Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Clinical cardiology 1999;22(8 Suppl):IV30-6.
1999: Christopher P Cannon; Assaad Sayah; Ron M Walls
Prehospital thrombolysis: an idea whose time has come.
Clinical cardiology 1999;22(8 Suppl):IV10-9.
1999: Christopher P Cannon
Breaking the therapeutic barriers: new strategies for acute coronary syndromes.
Clinical cardiology 1999;22(8 Suppl):IV1-2.
1999: C Michael Gibson; KA Ryan; M Kelley; MJ Rizzo; R Mesley; S Murphy; J Swanson; Susan J Marble; J Theodore Dodge; Robert P Giugliano; Christopher P Cannon; Elliott M Antman
Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group.
American heart journal 1999;137(6):1179-84.
1999: Frans Van de Werf; Christopher P Cannon; A Luyten; K Houbracken; Carolyn H McCabe; S Berioli; Erich Bluhmki; H Sarelin; F Wang-Clow; NL Fox; Eugene Braunwald
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
American heart journal 1999;137(5):786-91.
1999: C Michael Gibson; Sabina A Murphy; MJ Rizzo; KA Ryan; Susan J Marble; Carolyn H McCabe; Christopher P Cannon; Frans Van de Werf; Eugene Braunwald
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group.
Circulation 1999;99(15):1945-50.
1999: Christopher P Cannon
Advances in the medical management of acute coronary syndromes.
Journal of thrombosis and thrombolysis 1999;7(2):171-89.
1999: Christopher P Cannon; J Dingemanse; CH Kleinbloesem; T Jannett; K M Curry; C P Valcke
Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers.
Circulation 1999;99(6):751-6.
1999: William S Weintraub; Steven D Culler; Andrzej S Kosinski; Edmund R Becker; Elizabeth M Mahoney; JC Burnette; John A Spertus; David Feeny; D J Cohen; Harlan Krumholz; S G Ellis; Laura A Demopoulos; D Robertson; Steve J Boccuzzi; Eliav Barr; Christopher P Cannon
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.
The American journal of cardiology 1999;83(3):317-22.
1999: Christopher P Cannon; E B Johnson; M Cermignani; Benjamin M Scirica; Mark J Sagarin; Ron M Walls
Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction.
Clinical cardiology 1999;22(1):17-20.
1999: Milenko J Tanasijevic; Christopher P Cannon; Elliott M Antman
The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease.
Clinical cardiology 1999;22(1):13-6.
1999: Jorge R Kizer; Christopher P Cannon; Carolyn H McCabe; HS Mueller; M J Schweiger; V G Davis; Rebecca Perritt; E M Antman
Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.
American heart journal 1999;137(1):79-92.
1998: Christopher P Cannon; C Michael Gibson; Carolyn H McCabe; A A Adgey; M J Schweiger; Rafael Sequeira; G Grollier; Robert P Giugliano; M Frey; HS Mueller; Richard M Steingart; W D Weaver; Frans Van de Werf; Eugene Braunwald
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Circulation 1998;98(25):2805-14.
1998: Christopher P Cannon; William S Weintraub; Laura A Demopoulos; Debbie H Robertson; G J Gormley; Eugene Braunwald
Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
The American journal of cardiology 1998;82(6):731-6.
1998: Christopher P Cannon
Advances in the medical management of acute coronary syndromes.
Current opinion in cardiology 1998;13(5):327-47.
1998: Nathan R Every; Christopher P Cannon; C Granger; David J Moliterno; FV Aguirre; J D Talley; J Booth; Shelly K Sapp; James J Ferguson
Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation.
Journal of the American College of Cardiology 1998;32(2):387-92.
1998: Christopher P Cannon
Time to treatment of acute myocardial infarction revisited.
Current opinion in cardiology 1998;13(4):254-66.
1998: Mark J Sagarin; Christopher P Cannon; M S Cermignani; Benjamin M Scirica; Ron M Walls
Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effect.
The Journal of emergency medicine 1998;16(4):557-65.
1998: David A Morrow; Nader Rifai; Elliott M Antman; D L Weiner; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.
Journal of the American College of Cardiology 1998;31(7):1460-5.
1998: Robert A Kloner; Thomas Shook; E M Antman; Christopher P Cannon; Karin Przyklenk; K Yoo; C H McCabe; E Braunwald
Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B.
Circulation 1998;97(11):1042-5.
1998: Christopher P Cannon; Carolyn H McCabe; Steven Borzak; T D Henry; M D Tischler; HS Mueller; R Feldman; S T Palmeri; K Ault; S A Hamilton; J M Rothman; W F Novotny; Eugene Braunwald
Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Circulation 1998;97(4):340-9.
1998: Elliott M Antman; DB Sacks; Nader Rifai; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.
Journal of the American College of Cardiology 1998;31(2):326-30.
1997: C Michael Gibson; J Theodore Dodge; M Goel; EN Al-Mousa; M Rizzo; C McLean; K Ryan; A Sparano; Susan J Marble; W L Daley; Christopher P Cannon; Elliott M Antman
Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flow.
The American journal of cardiology 1997;80(12):1536-9.
1997: Milenko J Tanasijevic; Christopher P Cannon; DR Wybenga; George A Fischer; C Grudzien; C Michael Gibson; James W Winkelman; Elliott M Antman; Eugene Braunwald
Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A.
American heart journal 1997;134(4):622-30.
1997: Christopher P Cannon; P J Sharis; MJ Schweiger; Carolyn H McCabe; DJ Diver; P K Shah; Rafael Sequeira; R M Greene; Rebecca Perritt; W K Poole; Eugene Braunwald
Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction.
The American journal of cardiology 1997;80(6):696-9.
1997: C Michael Gibson; Susan J Marble; MJ Rizzo; J Moynihan; C McLean; K Ryan; A Sparano; Robert N Piana; C McCabe; Christopher P Cannon
Relation between injections before 90-minute angiography and coronary patency: results of the thrombolysis in myocardial infarction 4 trial.
American heart journal 1997;134(3):351-4.
1997: Christopher P Cannon; Carolyn H McCabe; Peter H Stone; W J Rogers; M Schactman; Bruce W Thompson; D J Pearce; DJ Diver; C Kells; Ted Feldman; M Williams; R S Gibson; M W Kronenberg; LI Ganz; H Vernon Anderson; Eugene Braunwald
The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia.
Journal of the American College of Cardiology 1997;30(1):133-40.
1997: C Michael Gibson; Christopher P Cannon; R M Greene; Rafael Sequeira; R D Margorien; F Leya; DJ Diver; Donald S Baim; Eugene Braunwald
Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial.
The American journal of cardiology 1997;80(1):21-6.
1997: H Vernon Anderson; R S Gibson; P H Stone; Christopher P Cannon; FV Aguirre; B Thompson; G L Knatterud; E Braunwald
Management of unstable angina pectoris and non-Q-wave acute myocardial infarction in the United States and Canada (the TIMI III Registry).
The American journal of cardiology 1997;79(11):1441-6.
1997: Christopher P Cannon; Carolyn H McCabe; Peter H Stone; M Schactman; B Thompson; P Theroux; R S Gibson; Ted Feldman; N S Kleiman; G H Tofler; J E Muller; B R Chaitman; Eugene Braunwald
Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB).
The American journal of cardiology 1997;79(3):253-8.
1997: Christopher P Cannon; Carolyn H McCabe; C Michael Gibson; M Ghali; Rafael Sequeira; G R McKendall; J Breed; N B Modi; NL Fox; R P Tracy; T W Love; Eugene Braunwald
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
Circulation 1997;95(2):351-6.
1996: Elliott M Antman; Milenko J Tanasijevic; B Thompson; M Schactman; Carolyn H McCabe; Christopher P Cannon; George A Fischer; A Y Fung; C Thompson; DR Wybenga; Eugene Braunwald
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.
The New England journal of medicine 1996;335(18):1342-9.
1996: Y Birnbaum; Robert A Kloner; S Sclarovsky; Christopher P Cannon; C H McCabe; V G Davis; B L Zaret; F J Wackers; Eugene Braunwald
Distortion of the terminal portion of the QRS on the admission electrocardiogram in acute myocardial infarction and correlation with infarct size and long-term prognosis (Thrombolysis in Myocardial Infarction 4 Trial).
The American journal of cardiology 1996;78(4):396-403.
1996: Richard C Becker; Christopher P Cannon; E G Bovill; R P Tracy; B Thompson; Genell L Knatterud; A Randall; B Braunwald
Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial)
The American journal of cardiology 1996;78(2):142-7.
1996: Richard C Becker; Christopher P Cannon; R P Tracy; B Thompson; E G Bovill; P Desvigne-Nickens; A M Randall; G Knatternud; Eugene Braunwald
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
American heart journal 1996;131(3):421-33.
1996: C Michael Gibson; Christopher P Cannon; W L Daley; J Theodore Dodge; B Alexander; Susan J Marble; Carolyn H McCabe; L Raymond; T Fortin; W K Poole; Eugene Braunwald
TIMI frame count: a quantitative method of assessing coronary artery flow.
Circulation 1996;93(5):879-88.
1995: J Fuchs; Christopher P Cannon
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Circulation 1995;92(4):727-33.
1995: C R Boisjolie; SW Sharkey; Christopher P Cannon; D Brunette; J M Haugland; J L Thatcher; T D Henry
Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department.
The American journal of cardiology 1995;76(5):396-8.
1995: Christopher P Cannon; Eugene Braunwald
Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty.
Journal of the American College of Cardiology 1995;25(7 Suppl):30S-37S.
1995: Christopher P Cannon; B Thompson; Carolyn H McCabe; H S Mueller; J M Kirshenbaum; S Herson; J B Nasmith; Bernard R Chaitman; Eugene Braunwald
Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials.
The American journal of cardiology 1995;75(15):977-81.
1995: Christopher P Cannon
Improved management of unstable angina and non-Q-wave MI.
Contemporary internal medicine 1995;7(5):11-2, 15-6, 19-24.
1995: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Elliott M Antman
The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade.
Journal of interventional cardiology 1995;8(2):117-35.
1995: C Michael Gibson; Christopher P Cannon; Robert N Piana; JA Breall; Barry L Sharaf; M Flatley; B Alexander; DJ Diver; Carolyn H McCabe; Greg C Flaker
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Journal of the American College of Cardiology 1995;25(3):582-9.
1995: Robert A Kloner; T Shook; Karin Przyklenk; V G Davis; L Junio; R V Matthews; S Burstein; M Gibson; W K Poole; Christopher P Cannon
Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning?
Circulation 1995;91(1):37-45.
1994: Christopher P Cannon; Carolyn H McCabe; DJ Diver; S Herson; R M Greene; P K Shah; Rafael Sequeira; F Leya; J M Kirshenbaum; R D Magorien
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Journal of the American College of Cardiology 1994;24(7):1602-10.
1994: Christopher P Cannon
Advances in the treatment of acute MI.
Contemporary internal medicine 1994;6(8):11-5, 20-6.
1994: G C Flaker; J Bartolozzi; V Davis; C McCabe; Christopher P Cannon
Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction.
Archives of internal medicine 1994;154(13):1492-6.
1994: Christopher P Cannon; Carolyn H McCabe; T D Henry; M J Schweiger; R S Gibson; H S Mueller; R C Becker; N S Kleiman; J M Haugland; J L Anderson
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Journal of the American College of Cardiology 1994;23(5):993-1003.
1993: Eugene Braunwald; Christopher P Cannon; C H McCabe
Use of composite endpoints in thrombolysis trials of acute myocardial infarction.
The American journal of cardiology 1993;72(19):3G-12G.
1993: Christopher P Cannon; J M Maraganore; Joseph Loscalzo; A McAllister; K Eddings; D George; Andrew P Selwyn; B Adelman; I Fox; Eugene Braunwald
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
The American journal of cardiology 1993;71(10):778-82.
1992: Eugene Braunwald; Christopher P Cannon; C H McCabe
An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point.
Circulation 1992;86(2):683-7.